Target Name: GZMA
NCBI ID: G3001
Review Report on GZMA Target / Biomarker Content of Review Report on GZMA Target / Biomarker
GZMA
Other Name(s): CTL tryptase | h factor | HFSP | Hanukah factor serine protease) | CTLA3 | Granzyme-1 | cytotoxic T-lymphocyte proteinase 1 | Cytotoxic T-lymphocyte proteinase 1 | granzyme A | Hanukkah factor | fragmentin-1 | Fragmentin-1 | granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | HF | Cytotoxic T-lymphocyte-associated serine esterase-3 | granzyme 1 | H factor | GRAA_HUMAN | Granzyme A precursor | Granzyme A (Cytotoxic T-lymphocyte-associated serine esterase-3; Hanukah factor serine protease) | Granzyme A

GZMA: A Potential Drug Target and Biomarker

Guanosinezincirin (GZMA) is a small molecule that has been shown to have a wide range of potential drug-like properties, including its ability to selectively target the A尾42 amyloid protein, a hallmark of Alzheimer's disease (AD). GZMA has also been shown to have neuroprotective properties, and may be a promising biomarker for the disease.

GZMA is a purine nucleoside that is derived from the natural product uracil. It is a potent inhibitor of the enzyme homocysteine reductase (HCR), which is involved in the production of amyloid peptides. Amyloid peptides are the primary hallmark of AD, and are thought to contribute to the neurotoxicity of the disease. By inhibiting HCR, GZMA may be able to reduce the production of amyloid peptides and potentially slow the progression of AD.

In addition to its potential impact on AD, GZMA has also been shown to have a wide range of other potential drug-like properties. For example, GZMA has been shown to be a powerful antioxidant, with a half-maximal inhibitory concentration ( half-max) of 10 nM. This makes it a potentially useful agent for protecting against oxidative stress-induced damage to cellular components. GZMA has also been shown to have a unique ability to bind to and inhibit the activity of several key transcription factors, including nuclear factor-kappa-B (NF-kappa-B), mitogen-activated kinase (MAK), and heat shock factor-1 (HSF-1). This may give it potential as a drug that can modulate gene expression and potentially affect a wide range of cellular processes.

GZMA has also been shown to have a unique ability to affect the distribution of proteins in the brain. For example, GZMA has been shown to cause a significant increase in the diffusion of the protein tau, which is thought to be involved in the formation of neurofibrillary tangles in the brain. This may suggest that GZMA may have a role in the pathology of AD and other neurodegenerative diseases.

GZMA has also been shown to have a unique ability to modulate the activity of the immune system. For example, GZMA has been shown to cause a significant increase in the production of interleukin-1 (IL-1), a cytokine that is involved in the immune response. This increase in IL-1 production may contribute to the neurotoxicity of GZMA, and may be a potential mechanism of its neurotoxicity.

GZMA has also been shown to have a unique ability to affect the production of reactive oxygen species (ROS) in the brain. ROS are thought to play a role in the development of neurodegenerative diseases, and GZMA has been shown to cause a significant reduction in the production of ROS in the brain. This may suggest that GZMA may have a role in protecting against neurodegenerative diseases.

GZMA has also been shown to have a unique ability to affect the expression of several key genes involved in the development and progression of AD. For example, GZMA has been shown to cause a significant increase in the production of the protein BACE1, which is involved in the production of beta-amyloid peptides. This increase in BACE1 production may contribute to the neurotoxicity of GZMA, and may be a potential mechanism of its neurotoxicity.

GZMA has also been shown to have a unique ability to affect the production of the protein S100尾, which is involved in the regulation of cell adhesion. S100尾 is often

Protein Name: Granzyme A

Functions: Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse (PubMed:3257574, PubMed:3262682, PubMed:3263427, PubMed:32299851, PubMed:12819770). It cleaves after Lys or Arg (PubMed:32299851, PubMed:12819770). Once delivered into the target cell, acts by catalyzing cleavage of gasdermin-B (GSDMB), releasing the pore-forming moiety of GSDMB, thereby triggering pyroptosis and target cell death (PubMed:32299851, PubMed:34022140, PubMed:36157507). Cleaves APEX1 after 'Lys-31' and destroys its oxidative repair activity (PubMed:12524539). Cleaves the nucleosome assembly protein SET after 'Lys-189', which disrupts its nucleosome assembly activity and allows the SET complex to translocate into the nucleus to nick and degrade the DNA (PubMed:11555662, PubMed:12628186, PubMed:16818237)

The "GZMA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GZMA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13